Sonoma Pharmaceuticals (NASDAQ:SNOA) PT Set at $11.00 by Maxim Group

Maxim Group set a $11.00 price objective on Sonoma Pharmaceuticals (NASDAQ:SNOA) in a research note issued to investors on Friday, November 17th. The firm currently has a buy rating on the stock.

Separately, ValuEngine downgraded Sonoma Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 1st.

Sonoma Pharmaceuticals (NASDAQ SNOA) traded down $0.17 during trading on Friday, hitting $4.85. The company had a trading volume of 9,705 shares, compared to its average volume of 30,470. The company has a quick ratio of 4.56, a current ratio of 5.37 and a debt-to-equity ratio of 0.01. Sonoma Pharmaceuticals has a 1-year low of $4.16 and a 1-year high of $8.25.

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Janus Capital Management LLC boosted its holdings in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 41.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,926 shares of the company’s stock after purchasing an additional 11,053 shares during the period. Janus Capital Management LLC owned 0.89% of Sonoma Pharmaceuticals worth $272,000 as of its most recent SEC filing. 9.39% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Sonoma Pharmaceuticals (NASDAQ:SNOA) PT Set at $11.00 by Maxim Group” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply